| Trial Identifier: | D8664R00002 |
| Sponsor: | AstraZeneca |
| NCTID:: | NCT05184257 |
| Start Date: | January 2022 |
| Primary Completion Date: | August 2023 |
| Study Completion Date: | February 2024 |
| Condition: | Breast Cancer |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
No documents have been posted yet.
| Country | Location |
|---|---|
| China | Beijing, China, 100021 |
| China | Changsha, China, 410013 |
| China | Changsha, China |
| China | Chengdu, China |
| China | Guangan, China |
| China | Guangyuan, China |
| China | Guangzhou, China, 510060 |
| China | Guangzhou, China |
| China | Haerbin, China, 150081 |
| China | Hangzhou, China |
| China | HuHeHaoTe, China |
| China | Jinan, China, 250117 |
| China | Nantong, China |
| China | Shanghai, China, 200032 |
| China | Suzhou, China, 215006 |
| China | Suzhou, China |
| China | Taiyuan, China |
| China | Tianjin, China, 300060 |
| China | Xining, China |
| China | Zhengzhou, China, 450008 |
Powered by
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.
Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company